The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. [electronic resource]
Producer: 20051209Description: S21-5 p. digitalISSN:- 1478-6362
- Abatacept
- Animals
- Antigen Presentation
- Antigens, CD
- Antigens, Differentiation -- genetics
- Antirheumatic Agents -- pharmacology
- Arthritis, Experimental -- drug therapy
- Arthritis, Rheumatoid -- drug therapy
- Autoimmune Diseases -- drug therapy
- B7-1 Antigen -- immunology
- B7-2 Antigen -- immunology
- CD28 Antigens -- immunology
- CTLA-4 Antigen
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Double-Blind Method
- Drug Evaluation, Preclinical
- Female
- Humans
- Immunoconjugates -- pharmacology
- Immunoglobulin Fc Fragments -- genetics
- Lymphocyte Activation -- drug effects
- Male
- Mice
- Middle Aged
- Multicenter Studies as Topic
- Pilot Projects
- Protein Structure, Tertiary
- Receptors, Antigen, T-Cell -- immunology
- Recombinant Fusion Proteins -- therapeutic use
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.